05.11.2008 – 18:30

Personalising Cancer Care - An Invitation

Ingelheim, Germany, November 5 (ots/PRNewswire)

- For Non-US Healthcare Media

Can the quest for personalised medicine in cancer therapy ever be
realised? And how far have we come in the journey to personalised
cancer care?

What lies ahead from a clinical research perspective will be
discussed in an international media webcast entitled "Probable or
pipedream: could new cancer targets change the outlook for
personalised medicine?", in conjunction with the Multi-disciplinary
Symposium in Thoracic Oncology.

Eminent experts in the field, including Dr Nasser Hanna, Dr Paul
Bunn and Dr Vera Hirsh will discuss and debate future directions in
the process of cancer drug development and how the oncology community
is working to discover more intelligent and innovative treatment
solutions for the individual cancer patient.

Available online from 17 November 2008

To register please click the link below

http://www.personalisingcancercare.com

If you have difficulties registering please contact:
    Joy Burgess
    Ogilvy Healthworld
    Tel: +44(0)207-108-6519
    Tel: +44(0)7843098437
    Email:  joy.burgess@ogilvyhealthworld.com

Contact:

Joy Burgess, Ogilvy Healthworld, Tel: +44(0)207-108-6519, Tel:
+44(0)7843098437, Email: joy.burgess@ogilvyhealthworld.com

Plus de actualités: Boehringer Ingelheim

Tous Actualités Tous

31.10.2008 – 14:15
Largest Study of its Kind Reveals Low Sexual Desire is Most Common Female Sexual Problem
Ingelheim, Germany (ots/PRNewswire) - - 1 in 10 Women Experience Distress Associated With the Most Common Form of Female Sexual Dysfunction, yet the Condition Remains Largely Under-Recognised and Under-Diagnosed - For non-US media only Results from the PRESIDE*(1) survey, the largest study assessing the prevalence of female sexual problems, show that ...
plus
23.10.2008 – 17:10
Telmisartan (MICARDIS(R)) as Effective as Ramipril But With Better Long-Term Tolerability in High-Risk Cardiovascular Asian Patients
Beijing (ots/PRNewswire) - New results from the landmark ONTARGET(R) Trial show that, in Asian patients at high risk of cardiovascular disease (CVD), telmisartan (MICARDIS(R)) 80mg is as effective as, and significantly better tolerated than, ramipril 10mg in reducing the risk of cardiovascular death, heart ...
plus
22.10.2008 – 12:21
Boehringer Ingelheim Broadens Oncology Pipeline With Promising New Data for Potentially First in Class Plk1 Inhibitor
Ingelheim, Germany (ots/PRNewswire) - - BI 6727, a Highly Potent and Selective Plk1 inhibitor, Represents Latest Advance in Company's Plk1 Programme - For non-US Healthcare Media Boehringer Ingelheim's most promising new cell cycle kinase inhibitor and potentially first-in-class compound, BI 6727, ...
plus

Ces informations peuvent également vous intéresser

Personalising Cancer Care - An Invitation

Enterprises

Économie

Largest Study of its Kind Reveals Low Sexual Desire is Most Common Female Sexual Problem

Telmisartan (MICARDIS(R)) as Effective as Ramipril But With Better Long-Term Tolerability in High-Risk Cardiovascular Asian Patients

Boehringer Ingelheim Broadens Oncology Pipeline With Promising New Data for Potentially First in Class Plk1 Inhibitor